BLNDHIGH SIGNALFINANCIAL10-K

BLND shows substantial operating loss improvements despite a 23.7% revenue decline, with losses narrowing meaningfully across key metrics while reducing R&D spending significantly.

The company appears to be executing a cost-cutting strategy that's successfully reducing losses even as revenue contracts, suggesting improved operational discipline. However, the revenue decline raises questions about demand trends and whether the loss improvements are sustainable if top-line pressure continues.

Comparing 2026-03-16 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

BLND's financial picture shows a company prioritizing profitability over growth, with operating losses improving substantially while revenue declined by nearly a quarter year-over-year. The company reduced R&D expenses by 28.7% to $32.8M and saw net losses narrow considerably, though interest expense increased to $30.8M. Cash and current assets declined modestly while liabilities decreased, indicating tighter working capital management during this transitional period.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+84.3%
-$43.3M-$6.8M

Net income grew 84.3% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+56.2%
-$49.6M-$21.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
+32.1%
$1.3M$1.7M

Capital expenditure jumped 32.1% — major investment cycle underway; assess returns on deployment.

R&D Expense
P&L
-28.7%
$46.1M$32.8M

R&D spending cut 28.7% — could signal cost discipline or concerning reduction in innovation investment.

Interest Expense
P&L
+24.3%
$24.8M$30.8M

Interest costs rose 24.3% — monitor debt levels and coverage ratio in rising rate environment.

Revenue
P&L
-23.7%
$162.0M$123.6M

Revenue softened 23.7% — monitor whether this is cyclical or structural.

Cash & Equivalents
Balance Sheet
-20.8%
$55.0M$43.6M

Cash decreased 20.8% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-15.4%
$115.7M$97.9M

Current assets declined 15.4% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
-13.6%
$45.6M$39.5M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-13.1%
$47.2M$41.0M

Liabilities reduced 13.1% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-13
ADDED
As of March 2, 2026, there were 253,858,348 shares of the registrant's Class A common stock outstanding, 3,256,385 shares of the registrant's Class B common stock outstanding, and no shares of the registrant's Class C common stock outstanding.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 53 Item 6.
Management's Discussion and Analysis of Financial Condition and Results of Operations 55 Item 7A.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 123 Item 9A.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 125 I tem 1 3.
+7 more — sign up free →
REMOVED
As of March 3, 2025, there were 255,914,704 shares of the registrant's Class A common stock outstanding, 3,747,235 shares of the registrant's Class B common stock outstanding, and no shares of the registrant's Class C common stock outstanding.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 58 I tem 6.
Management's Discussion and Analysis of Financial Condition and Results of Operations 60 Item 7A.
C hanges in and Disagreements With Accountants on Accounting and Financial Disclosure 123 I tem 9A.
S ecurity Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 125 I tem 13.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →